Results 131 to 140 of about 53,405 (189)

Combined Therapy of ATRA and Imatinib Mesylate Decreases BCR-ABL and ABCB1/MDR1 Expression Through Cellular Differentiation in a Chronic Myeloid Leukemia Model. [PDF]

In Vivo, 2021
Pinto CA, DE Sousa Portilho AJ, Barbosa MC, DE Moraes MEA, DE Lemos JAR, Burbano RMR, Moreira-Nunes CA.   +6 more
europepmc   +1 more source

Use of a pH-responsive imatinib mesylate sustained-release hydrogel for the treatment of tendon adhesion by inhibiting PDGFRβ/CLDN1 pathway. [PDF]

Bioact Mater
Pang S, Wu R, Lv W, Zou J, Li Y, Li Y, Zhang P, Ma X, Wang Y, Liu S.   +9 more
europepmc   +1 more source

Safety outcomes of low versus high dose imatinib mesylate in patients with advanced, metastatic, or nonresectable gastrointestinal stromal tumors: A systematic review. [PDF]

Gastrointest Tract
Marucci MA, Lechner DW, Tafuto BA.
europepmc   +1 more source

A case-matched study of imatinib mesylate between different formulations on plasma trough concentration, adverse events, quality of life and outcomes in gastrointestinal stromal tumor patients. [PDF]

PLoS One
Zeng L, Cheng X, Li J, Zhang J, Wu X.
europepmc   +1 more source

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

Journal of Clinical Oncology, 2008
C. Blanke, G. Demetri, M. von Mehren, M. Heinrich, B. Eisenberg, J. Fletcher, C. Corless, C. Fletcher, P. Roberts, Daniela Heinz, Elisabeth Wehre, Z. Nikolova, H. Joensuu   +12 more
semanticscholar   +1 more source

Fibroblast Growth Factor 2 (FGF2) Activates Vascular Endothelial Growth Factor (VEGF) Signaling in Gastrointestinal Stromal Tumors (GIST): An Autocrine Mechanism Contributing to Imatinib Mesylate (IM) Resistance. [PDF]

Cancers (Basel)
Boichuk S, Dunaev P, Galembikova A, Valeeva E.   +3 more
europepmc   +1 more source

Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension: Results of the Randomized IMPRES Study

Circulation, 2013
M. Hoeper, R. Barst, R. Bourge, J. Feldman, A. Frost, N. Galiè, M. Gómez-Sánchez, F. Grimminger, E. Grünig, P. Hassoun, N. Morrell, A. Peacock, T. Satoh, G. Simonneau, V. Tapson, F. Torres, David Lawrence, D. Quinn, H. Ghofrani   +18 more
semanticscholar   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Imatinib mesylate

Reactions Weekly, 2003
Imatinib mesylate (imatinib) is an orally administered competitive inhibitor of the tyrosine kinases associated with the KIT protein (stem cell factor receptor), ABL protein and platelet-derived growth factor receptors. The KIT tyrosine kinase is abnormally expressed in gastrointestinal stromal tumour (GIST), a rare neoplasm for which there has been no
Monique P Curran, Katherine F Croom, Karen L Goa   +2 more
  +22 more sources

Imatinib Mesylate

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2009
Imatinib mesylate (Gleevec, Glivec [Novartis, Basel, Switzerland], formerly referred to as STI571 or CGP57148B) represents the paradigm of a new class of anticancer agents, so-called small molecules. They have a high selectivity against a specific molecular target known to be the cause for the establishment and maintenance of the malignant phenotype ...
C. Waller
semanticscholar   +8 more sources

Solubility measurement of a chemotherapeutic agent (Imatinib mesylate) in supercritical carbon dioxide: Assessment of new empirical model

Journal of Supercritical Fluids, 2019
For the first time, solubility of imatinib mesylate (as a paradigm for cancer chemotherapy) in SC-CO2 was determined. Experiments were performed at operating temperatures and pressures of 308.2–338.2 K and 120–270 bar, respectively.
Gholamhossein Sodeifian, Seyed Ali Sajadian, Fariba Razmimanesh   +2 more
exaly   +2 more sources